Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Said to be Planning 67 Million Euro IPO

NEW YORK, July 7 (GenomeWeb News) - Epigenomics is planning an initial public offering this month that could raise as much as €67 million ($83 million), according to news reports last week.

 

According to a July 3 Bloomberg report, the Berlin-based genomics diagnostic company plans to sell 4.6 million shares for between €11.90 and €14.50, which could raise between €55 million and €67 million.

 

An Epigenomics spokeswoman declined to comment when contacted by GenomeWeb News, citing legal requirements that prohibit releasing details of the company's IPO plans to US reporters.

 

The company's stock is scheduled to start trading on the Frankfurt Stock Exchange on July 16, according to Bloomberg.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.